A.I. Burnasyan FMBC clinical bulletin. 2023 № 3
D.A. Andreev1, A. A. Zavyalov2, S.E. Varlamova2
Results of the ESMO Congress: Immunotherapy for NSCLC
1Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, Moscow, Russia
2International Office, State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russiа
Contact person: Andreev Dmitriy Anatol’evich: AndreevDA@zdrav.mos.ru
Abstract
Every year, more than 1.5 million people die from lung cancer (LC) worldwide. In a number of industrialized countries, LC is the dominant oncological disease. The beginning of autumn 2022 was marked by a regular landmark event in the professional environment of oncologists: the Annual Congress of the European Society for Medical Oncology (ESMO) was held in Paris. The congress presented and discussed innovative developments in immunotherapy for patients with advanced NSCLC. The purpose of this work was to summarize the current clinical developments in combined immunotherapy for advanced NSCLC discussed at the ESMO Annual Congress – September 2022: IFCT-1701 studies; KEYNOTE-407; KEYNOTE-189; IPSOS; INCREASE.
The systematic search for effective antitumor immunodrugs continues, and a comprehensive modernization of the protocols for their use is being carried out. This allows us to hope for a cardinal increase in life expectancy and improvement in its quality in patients with NSCLC, even at the most advanced stages.
Keywords: non-small cell lung cancer, clinical trials, immunotherapy
For citation: Andreev DA, Zavialov AA, Varlamova SE. Results of the ESMO Congress: Immunotherapy for NSCLC. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2023.3:55-60. (In Russian) DOI: 10.33266/2782-6430-2023-3-55-60
REFERENCES
1. Zhang Y, Ren J-S, Huang H-Y et al. International trends in lung cancer incidence from 1973 to 2007. Cancer Med. 2018;7:1479–89.
2. Slugin EN, Levchenko EV, Imyanitov EN et al. The role of EGFR mutation testing in the choice for surgical tactics in NSCLC treatment. Problems of oncology. 2021;67:315–22 (in Russ.).
3. Longkanker Nederland. IKNL. Cijfers over longkanker. 2021. https://www.longkankernederland.nl/longkanker/statistieken. Accessed 20 Aug 2021.
4. Kaprin AD, Starinsky VV, Shakhzadova AO, red. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen – branch of the Federal State Budgetary Institution “NMITs Radiology” of the Ministry of Health of Russia; 2020 (in Russian)
5. Andreev DA, Zavialov AA, Polyakova KI et al. Tyrosine kinase inhibitors in the treatment of advanced lung cancer using the example of the Moscow city drug benefit system. Pulmonology. 2020;30:463–72. (in Russ.).
6. Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F et al. Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017;49:1601520.
7. Wang Y, Hu G, Wang Z. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy. Onco Targets Ther. 2017;Volume 10:3557–66.
8. Stilidy IS, Gevorkyan TG, Shpak AG. Improvement of indicators of the federal project “Fight against oncological diseases”. Bulletin of Roszdravnadzor. 2021;1:46–53. (in Russ.)
9. American Society of Clinical Oncology. ASCO Annual Meeting 2022. 2022. https://meetings.asco.org/meetings/2022-asco-annual-meeting/
288/program-guide/scheduled-sessions. Accessed 14 Jun 2022.
10. MEDtalks, Smit E, Hendriks L. ESMO 2022 journaal | Longcarcinoom. 2022. https://www.medtalks.nl/esmo2022-longcarcinoom. Accessed 18 Oct 2022.
11. Russian Society of Clinical Oncology (RUSSCO). News of oncology. 2022. https://www.rosoncoweb.ru/news/oncology/. Accessed 21 Oct 2022. (in Russ.).
12. Zalcman G, Madroszyk Flandin A, Molinier O et al. Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial. Ann Oncol. 2022;33 suppl_7:S448-554.
13. Novello S, Kowalski DM, Luft A et al. 974MO – 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Ann Oncol. 2022;33 suppl_7:S448-554.
14. National Library of Medicine. Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189). 2022. https://clinicaltrials.gov/ct2/show/NCT02578680. Accessed 21 Oct 2022.
15. Garassino MC, Gadgeel SM, Speranza G et al. 973MO – KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC. Ann Oncol. 2022;33 suppl_7:S448-554
16. National Library of Medicine. A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]. 2022. https://www.clinicaltrials.
gov/ct2/show/NCT02409342. Accessed 21 Oct 2022.
17. Lee SM, Schulz C, Prabhash K et al. LBA11 – IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Ann Oncol. 2022;33 suppl_7:S808-869.
18. Dickhoff C, Senan S, Schneiders FL et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. BMC Cancer. 2020;20:764.
19. Bahce I, Dickhoff C, Schneiders FL et al. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial. Ann Oncol. 2022;33 suppl_7:S438-447.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 15.07.2023. Accepted for publication: 16.08.2023